Back to Neurology

OUR EXPERTISE AND AND SERVICES AVAILABLE IN

Multiple Sclerosis

Overview

Spherix’s coverage of the multiple sclerosis market focuses on the dynamic and expanding landscape of disease modifying treatment. We are uniquely positioned to provide insights at the subtype level informed by prescribing patterns and treatment philosophies as the armamentarium evolves with new branded and generic options.

Services Available

Trending market evolution

  • Multiple Sclerosis (US) - quarterly, n=100

  • Multiple Sclerosis (EU) - semiannual, n=250

  • Multiple Sclerosis (Canada) - semiannual, n=250

Exploring the patient journey

  • DMT New Starts in MS (US) - n=1,000 patient charts

  • DMT Switching in MS (US) - n=1,000 patient charts

  • DMT Switching in MS (EU) -n=1,250 patient charts

  • Progressive Forms of MS (US) -n=750 patient charts

Benchmarking new brand performance

  • Kesimpta (Novartis) in Multiple Sclerosis (US)

  • Ponvory (Janssen) in Multiple Sclerosis (US)*

  • Zeposia (BMS) in Multiple Sclerosis (US)

*Pending approvals and launch

Gauging impact of disruptive events

  • MS Market Landscape (US)

  • Multi-Specialty Impact of COVID-19 (US)

  • Ocrevus in MS – Evolution of a Blockbuster (US)

Learn more about our services

  • HOW CAN WE PARTNER TOGETHER?

    Get more information on Multiple Sclerosis Coverage